



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Vincent P. Stanton, Jr. Art Unit : 1655
Serial No. : 09/648,123 Examiner : C. Wilder
Filed : August 25, 2000
Title : GENE SEQUENCE VARIATIONS WITH UTILITY IN DETERMINING THE
TREATMENT OF DISEASE, IN GENES RELATING TO DRUG PROCESSING

RECEIVED
DEC 11 2002

TECH CENTER 1600/2900

BOX AF
Commissioner for Patents
Washington, D.C. 20231

RECEIVED

DEC 23 2002

TECH CENTER 1600/2900

RESPONSE

In response to the action mailed May 31, 2002, please amend the application as follows:

In the claims:

Please cancel claims 17-26.

Add new claims 27-34

TECH CENTER 1600/2900

RECEIVED
DEC 20 2002
H13/B
Punkett
12/24/02

B1
--27. An isolated nucleic acid probe comprising at least 15 nucleotides which hybridizes under stringent conditions to a variant human cytochrome P-450 (CYP3A4) gene having a T to C variance at nucleotide 732 and does not hybridize under stringent conditions to a human cytochrome P-450 (CYP3A4) gene not having a T to C variance at nucleotide 732.

28. The probe of claim 27 wherein the probe comprises fewer than 200 nucleotides.

29. The probe of claim 27 wherein the probe comprises fewer than 100 nucleotides.

30. The probe of claim 27 wherein the probe comprises DNA.

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit

December 2, 2002

Signature

Lisa G. Gray

Typed or Printed Name of Person Signing Certificate